Written by Private MD Labs Medical Writing Team • Last Updated: September 8, 2025
Cystic fibrosis-related diabetes (CFRD) is a unique form of diabetes that develops in people with cystic fibrosis, affecting approximately 20% of adolescents and up to 50% of adults with CF. Unlike Type 1 or Type 2 diabetes, CFRD has distinct characteristics that require specialized monitoring and management approaches.
This test measures average blood glucose levels over the past 2-3 months by evaluating the percentage of hemoglobin that has glucose attached to it. The eAG (estimated average glucose) provides an easy-to-understand number that correlates with daily glucose meter readings. For CFRD patients, this test is crucial for long-term glucose monitoring and helps healthcare providers assess how well diabetes management is working, which is particularly important since good glucose control can help maintain lung function and nutritional status in people with cystic fibrosis.
While CFRD diagnosis typically involves glucose tolerance testing, ongoing blood glucose monitoring through laboratory tests is fundamental for effective management. Regular testing helps healthcare providers assess long-term glucose control, adjust treatment plans, and prevent complications that could further impact lung function and nutritional status in CF patients.
HbA1c targets for CFRD patients may differ from those with other types of diabetes, as the primary goal is to maintain adequate nutrition and lung function while preventing diabetes complications. Your healthcare team will interpret results in the context of your overall CF care plan and may adjust targets based on your individual health status and treatment response.
The information here is for educational purposes only and is not a substitute for professional medical advice. Always consult with your CF care team and endocrinologist for diagnosis, treatment, and monitoring of cystic fibrosis-related diabetes.